Hematopoietic stem cell transplant

Developed for: chronic granulomatous disease · combined immunodeficiency due to partial RAG1 deficiency · common variable immunodeficiency · DiGeorge syndrome · GATA2 deficiency with susceptibility to MDS/AML · immune dysregulation, autoimmunity, and autoinflammation · immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome · immunodeficiency 88
+4 more
· immunodysregulation with variable immunodeficiency and autoimmunity · Omenn syndrome · recombinase activating gene 2 deficiency · STAT3-related early-onset multisystem autoimmune disease
Investigated by: Paul Szabolcs

today NCT07284641 · Ph 2

2027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT07284641	May 2026 → May 2030 expected	DiGeorge syndrome, GATA2 deficiency with susceptibility to MDS/AML, Omenn syndrome, STAT3-related early-onset multisystem autoimmune disease +8	Paul Szabolcs	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Hematopoietic stem cell transplant	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284641 ↗